{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:12:57Z","timestamp":1792696377410,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Recent advances in the treatment of acute myeloid leukemia (AML) and optimized supportive care have improved survival outcomes. However, infections during remission induction chemotherapy remain a leading cause of morbidity and mortality. While antifungal prophylaxis is standard, the role of routine antibacterial prophylaxis is increasingly debated due to adverse effects and resistance. This study aimed to characterize infectious complications in a real-world AML cohort receiving induction chemotherapy without routine antibacterial prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 103 adults with newly diagnosed AML who underwent intensive induction therapy at LMU University Hospital between January 2019 and December 2022. All patients received antifungal prophylaxis whereas antibacterial fluoroquinolone (FQ) prophylaxis was not administered. We assessed febrile episodes, clinically and microbiologically documented infections, ICU\/IMC admissions, and 30-\/90-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Febrile episodes occurred in almost all patients. Clinically documented infections accounted for 29.8% and microbiologically confirmed infections for 22.9% of febrile events. Bacteraemia was evenly distributed between Gram-positive and Gram-negative pathogens; multidrug resistance was rare. Proven or probable invasive fungal infections occurred in 6.8% of patients. In 47.2% of cases, the cause of fever remained unknown. Infection-related 30-day mortality was 4.9%. Factors associated with increased 30-day mortality included age\u2009\u2265\u200965 years, ECOG\u2009\u2265\u20092, secondary AML, and ICU\/IMC admission for infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Infections remain a major challenge during AML induction therapy. Our findings suggest that FQ prophylaxis should be reevaluated in this setting, focussing on a more individualized approach. In addition, novel diagnostic tools are urgently needed to enable earlier and more targeted infection management in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02651-4","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:43:16Z","timestamp":1759315396000},"page":"243-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3283-700X","authenticated-orcid":false,"given":"S.","family":"Ehrlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Eufinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jurinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mansournia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2651_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"2651_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, Pautas C, Terr\u00e9 C, et al. Gemtuzumab Ozogamicin for de Novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104:113\u20139. https:\/\/doi.org\/10.3324\/haematol.2018.188888","journal-title":"Haematologica"},{"key":"2651_CR3","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/jco.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392. https:\/\/doi.org\/10.1200\/jco.2017.77.6112","journal-title":"J Clin Oncol"},{"key":"2651_CR4","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/j.ijid.2009.02.021","volume":"14","author":"E Lech-Maranda","year":"2010","unstructured":"Lech-Maranda E, Seweryn M, Giebel S, et al. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with Daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish adult leukemia group (PALG). Int J Infect Dis. 2010;14:e132\u2013140. https:\/\/doi.org\/10.1016\/j.ijid.2009.02.021","journal-title":"Int J Infect Dis"},{"key":"2651_CR5","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3109\/10428194.2011.636812","volume":"53","author":"G Cannas","year":"2012","unstructured":"Cannas G, Pautas C, Raffoux E, et al. Infectious complications in adult acute myeloid leukemia: analysis of the acute leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma. 2012;53:1068\u201376. https:\/\/doi.org\/10.3109\/10428194.2011.636812","journal-title":"Leuk Lymphoma"},{"key":"2651_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41409-020-01003-0","volume":"56","author":"T Rixecker","year":"2021","unstructured":"Rixecker T, Lesan V, Ahlgrimm M, et al. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy. Bone Marrow Transpl. 2021;56:195\u2013201. https:\/\/doi.org\/10.1038\/s41409-020-01003-0","journal-title":"Bone Marrow Transpl"},{"key":"2651_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bjh.13113","volume":"167","author":"WJ van der Velden","year":"2014","unstructured":"van der Velden WJ, Herbers AH, Netea MG, et al. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. Br J Haematol. 2014;167:441\u201352. https:\/\/doi.org\/10.1111\/bjh.13113","journal-title":"Br J Haematol"},{"key":"2651_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41375-022-01786-9","volume":"37","author":"CS Walti","year":"2023","unstructured":"Walti CS, Halpern AB, Xie H, et al. Infectious complications after intensive chemotherapy with CLAG-M versus 7\u2009+\u20093 for AML and other high-grade myeloid neoplasms. Leukemia. 2023;37:298\u2013307. https:\/\/doi.org\/10.1038\/s41375-022-01786-9","journal-title":"Leukemia"},{"key":"2651_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5507\/bp.2022.010","volume":"167","author":"M Cernan","year":"2023","unstructured":"Cernan M, Szotkowski T, Hubacek J, et al. Infectious complications of induction treatment for acute myeloid leukaemia using the 7\u2009+\u20093 protocol without antibiotic prophylaxis \u2013\u200915 years of experience of one clinical site. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023;167:236\u201345. https:\/\/doi.org\/10.5507\/bp.2022.010","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"2651_CR10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014570","author":"R Knabe","year":"2025","unstructured":"Knabe R, Muller P, Schliemann C, et al. Gastrointestinal toxicity of Gemtuzumab ozogamicin: Real-life data from the AMLCG, SAL and CELL study groups. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2024014570","journal-title":"Blood Adv"},{"key":"2651_CR11","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/s2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7\u2009+\u20093 cytarabine and Daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481\u201391. https:\/\/doi.org\/10.1016\/s2352-3026(21)00134-4","journal-title":"Lancet Haematol"},{"key":"2651_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71:1367\u201376. https:\/\/doi.org\/10.1093\/cid\/ciz1008","journal-title":"Clin Infect Dis"},{"key":"2651_CR13","doi-asserted-by":"publisher","unstructured":"Cattaneo C, Marchesi F, Terrenato I, et al. High incidence of invasive fungal diseases in patients with FLT3-Mutated AML treated with midostaurin: results of a multicenter observational SEIFEM study. J Fungi (Basel). 2022;8. https:\/\/doi.org\/10.3390\/jof8060583","DOI":"10.3390\/jof8060583"},{"key":"2651_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or Itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348\u201359. https:\/\/doi.org\/10.1056\/NEJMoa061094","journal-title":"N Engl J Med"},{"key":"2651_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"2651_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s002770050285","volume":"74","author":"W Verbeek","year":"1997","unstructured":"Verbeek W, W\u00f6rmann B, Koch P, et al. S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol. 1997;74:205\u20138. https:\/\/doi.org\/10.1007\/s002770050285","journal-title":"Ann Hematol"},{"key":"2651_CR17","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","volume":"96","author":"WJ Heinz","year":"2017","unstructured":"Heinz WJ, Buchheidt D, Christopeit M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO). Ann Hematol. 2017;96:1775\u201392. https:\/\/doi.org\/10.1007\/s00277-017-3098-3","journal-title":"Ann Hematol"},{"key":"2651_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2005.00442.x","volume":"75","author":"M Gorschl\u00fcter","year":"2005","unstructured":"Gorschl\u00fcter M, Mey U, Strehl J, et al. Neutropenic Enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75:1\u201313. https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00442.x","journal-title":"Eur J Haematol"},{"key":"2651_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/myc.12960","volume":"62","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Hoenigl M, Lass-Fl\u00f6rl C, et al. Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European confederation of medical mycology. Mycoses. 2019;62:716\u201329. https:\/\/doi.org\/10.1111\/myc.12960","journal-title":"Mycoses"},{"key":"2651_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1513\/AnnalsATS.201304-097OC","volume":"10","author":"JB Garcia","year":"2013","unstructured":"Garcia JB, Lei X, Wierda W, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc. 2013;10:432\u201340. https:\/\/doi.org\/10.1513\/AnnalsATS.201304-097OC","journal-title":"Ann Am Thorac Soc"},{"key":"2651_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00432-022-03995-2","volume":"149","author":"R Tober","year":"2023","unstructured":"Tober R, Schnetzke U, Fleischmann M, et al. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. J Cancer Res Clin Oncol. 2023;149:1569\u201383. https:\/\/doi.org\/10.1007\/s00432-022-03995-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"2651_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1128\/aac.01525-13","volume":"58","author":"MZ Gomes","year":"2014","unstructured":"Gomes MZ, Mulanovich VE, Jiang Y, et al. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother. 2014;58:865\u201373. https:\/\/doi.org\/10.1128\/aac.01525-13","journal-title":"Antimicrob Agents Chemother"},{"key":"2651_CR23","doi-asserted-by":"publisher","unstructured":"Wasylyshyn AI, Linder KA, Kauffman CA, et al. Invasive fungal disease in patients with newly diagnosed acute myeloid leukemia. J Fungi (Basel). 2021;7. https:\/\/doi.org\/10.3390\/jof7090761","DOI":"10.3390\/jof7090761"},{"key":"2651_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.7326\/0003-4819-118-7-199304010-00003","volume":"118","author":"DJ Winston","year":"1993","unstructured":"Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495\u2013503. https:\/\/doi.org\/10.7326\/0003-4819-118-7-199304010-00003","journal-title":"Ann Intern Med"},{"key":"2651_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1086\/515128","volume":"28","author":"C Rotstein","year":"1999","unstructured":"Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian fluconazole prophylaxis study group. Clin Infect Dis. 1999;28:331\u201340. https:\/\/doi.org\/10.1086\/515128","journal-title":"Clin Infect Dis"},{"key":"2651_CR26","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1080\/10428194.2017.1361028","volume":"59","author":"MM Jalbut","year":"2018","unstructured":"Jalbut MM, Brunner AM, Amrein PC, et al. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma. 2018;59:988\u201391. https:\/\/doi.org\/10.1080\/10428194.2017.1361028","journal-title":"Leuk Lymphoma"},{"key":"2651_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/jac\/dkm514","volume":"61","author":"C Cattaneo","year":"2008","unstructured":"Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61:721\u20138. https:\/\/doi.org\/10.1093\/jac\/dkm514","journal-title":"J Antimicrob Chemother"},{"key":"2651_CR28","doi-asserted-by":"publisher","first-page":"e0178059","DOI":"10.1371\/journal.pone.0178059","volume":"12","author":"JR Conn","year":"2017","unstructured":"Conn JR, Catchpoole EM, Runnegar N, et al. Low rates of antibiotic resistance and infectious mortality in a cohort of high-risk hematology patients: A single center, retrospective analysis of blood stream infection. PLoS ONE. 2017;12:e0178059. https:\/\/doi.org\/10.1371\/journal.pone.0178059","journal-title":"PLoS ONE"},{"key":"2651_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/annonc\/mdl337","volume":"18","author":"DY Aksoy","year":"2007","unstructured":"Aksoy DY, Tanriover MD, Uzun O, et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic Enterocolitis. Ann Oncol. 2007;18:183\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdl337","journal-title":"Ann Oncol"},{"key":"2651_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14740\/jh1105","volume":"12","author":"R Babakhanlou","year":"2023","unstructured":"Babakhanlou R, Ravandi-Kashani F, Kontoyiannis DP. Neutropenic enterocolitis: an Uncommon, but fearsome complication of leukemia. J Hematol. 2023;12:59\u201365. https:\/\/doi.org\/10.14740\/jh1105","journal-title":"J Hematol"},{"key":"2651_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/cid\/cis998","volume":"56","author":"L Nesher","year":"2013","unstructured":"Nesher L, Rolston KV. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2013;56:711\u20137. https:\/\/doi.org\/10.1093\/cid\/cis998","journal-title":"Clin Infect Dis"},{"key":"2651_CR32","doi-asserted-by":"publisher","unstructured":"Fianchi L, Guolo F, Marchesi F, et al. Multicenter observational retrospective study on febrile events in patients with acute myeloid leukemia treated with Cpx-351 in Real-Life: the SEIFEM experience. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15133457","DOI":"10.3390\/cancers15133457"},{"key":"2651_CR33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1001\/archinternmed.2011.374","volume":"171","author":"L Pagano","year":"2011","unstructured":"Pagano L, Caira M, Nosari A, et al. Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart registry. Arch Intern Med. 2011;171:1502\u20133. https:\/\/doi.org\/10.1001\/archinternmed.2011.374","journal-title":"Arch Intern Med"},{"key":"2651_CR34","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.12688\/f1000research.19766.4","volume":"8","author":"JF Camargo","year":"2019","unstructured":"Camargo JF, Ahmed AA, Lindner MS, et al. Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. F1000Res. 2019;8:1194. https:\/\/doi.org\/10.12688\/f1000research.19766.4","journal-title":"F1000Res"},{"key":"2651_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/16078454.2019.1589706","volume":"24","author":"W Owattanapanich","year":"2019","unstructured":"Owattanapanich W, Chayakulkeeree M. Efficacy of Levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis. Hematology. 2019;24:362\u20138. https:\/\/doi.org\/10.1080\/16078454.2019.1589706","journal-title":"Hematology"},{"key":"2651_CR36","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1182\/blood-2022-169001","volume":"140","author":"S Kayal","year":"2022","unstructured":"Kayal S, Jain H, Nayak L, et al. Induction related mortality score in acute myeloid leukemia: prospective validation study (pRISM) of the hematology cancer consortium (HCC). Blood. 2022;140:3223\u20134. https:\/\/doi.org\/10.1182\/blood-2022-169001","journal-title":"Blood"},{"key":"2651_CR37","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41375-023-01930-z","volume":"37","author":"A Santoni","year":"2023","unstructured":"Santoni A, Malchiodi M, Zappone E, et al. Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis. Leukemia. 2023;37:1580\u20132. https:\/\/doi.org\/10.1038\/s41375-023-01930-z","journal-title":"Leukemia"},{"key":"2651_CR38","unstructured":"Agency EM. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. In: European Medicines Agency; 2019."},{"key":"2651_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/1471-2334-13-563","volume":"13","author":"FG De Rosa","year":"2013","unstructured":"De Rosa FG, Motta I, Audisio E, et al. Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing Levofloxacin prophylaxis. BMC Infect Dis. 2013;13:563. https:\/\/doi.org\/10.1186\/1471-2334-13-563","journal-title":"BMC Infect Dis"},{"key":"2651_CR40","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","volume":"100","author":"AY Classen","year":"2021","unstructured":"Classen AY, Henze L, von Lilienfeld-Toal M, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the infectious diseases working party of the German society of hematology and medical oncology (AGIHO\/DGHO). Ann Hematol. 2021;100:1603\u201320. https:\/\/doi.org\/10.1007\/s00277-021-04452-9","journal-title":"Ann Hematol"}],"updated-by":[{"DOI":"10.1007\/s15010-025-02705-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02651-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:33Z","timestamp":1770021573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02651-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2651"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02651-4","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s15010-025-02705-7","URL":"https:\/\/doi.org\/10.1007\/s15010-025-02705-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.E.: received speaker honoraria from Gilead Sciences. T.H.: received travel grants from Jazz Pharmaceuticals, received speaker honoraria from Astellas Pharma and advisory board fees from Servier and Jazz Pharmaceuticals. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}